{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-196974","form_type":"8-K","ticker":"BTMD","cik":"0001819253","company_name":"biote Corp.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.652340+00:00","generated_at":"2026-05-31T11:09:59.782954+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biote Q2 revenue $49.2M, net loss narrows to $10.5M; procedure revenue grows 7.8% sequentially","bullets":["Revenue of $49.2M; procedure revenue $38.4M, up 7.8% QoQ vs 6.6% in Q1.","Net loss of $(10.5)M (EPS $(0.19)) improved from $(13.1)M ($(0.25)) in Q2 2023.","Adjusted EBITDA of $12.7M; gross profit margin 68.9% with $1.2M inventory step-up from Asteria Health acquisition.","New clinics grew ~30% in H1 2024; 2024 full-year financial guidance reaffirmed.","BioteRx roll-out on track; management plans further geographic and therapeutic wellness expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-196974","json":"https://secwatch.observer/filing/0001193125-24-196974.json","markdown":"https://secwatch.observer/filing/0001193125-24-196974.md","text":"https://secwatch.observer/filing/0001193125-24-196974.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819253/000119312524196974/0001193125-24-196974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819253/000119312524196974/d831251d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:09:59.782954+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}